20020113
 Letters to the Editor -- Off-Label Drug Studies: Overcaution Is Risky   The Wall Street Journal,  Jan 14, 2002  Your front-page article on pharmaceutical research on unapproved drug uses ("Tactic of Drug Makers Is Raising Questions About Use of Research," Jan. 7) tries to cast doubt on an activity that most physicians find very useful. Yes, many of the studies are preliminary, and they might be funded by companies seeking higher sales. But physicians are aware of this; as the article concedes, they often have a healthy skepticism about these reports.   
